RankingsPricing
  1. US-listed companies
  2. Merck & Co., Inc.
  3. Raw

Merck & Co., Inc.MRK

Market cap
$251.9B
P/E ratio
SummaryFinancials
Back to summarized table
Dec 31,
2010		Dec 31,
2011		Dec 31,
2012		Dec 31,
2013		Dec 31,
2014		Dec 31,
2015		Dec 31,
2016		Dec 31,
2017		Dec 31,
2018		Dec 31,
2019		Dec 31,
2020		Dec 31,
2021		Dec 31,
2022		Dec 31,
2023		Dec 31,
2024
Net income9826,3926,2994,51711,9344,4593,9412,4186,1939,7777,082---17,133
Amortization----------1,8991,6362,0852,0442,395
Depreciation----------1,7261,6001,8001,8002,100
Intangible asset impairment charges-------------79239
(Income) loss from investments in equity securities, net-----------1,940-1,41934014
Charges for certain research and development asset acquisitions-----------1,556--3,456
Deferred income taxes-1,092-1,537669-330-2,600-764-1,521-2,621-509-556-668187-1,568-1,899-1,249
Share-based compensation509369335276278299300312348417475479541645761
Other--323-28-39995-757-313-269-978-18449-805-1,301-355-510
Accounts receivable1,0891,168-349-436554480619-297418-2941,0022,0336441,148244
Inventories-1,990678482365-79-805-206145911508855674161816835
Trade accounts payable124182-302522593-37278254230399724405-289-380182
Accrued and other current liabilities-1,444-717-3971,635-8-2,018-922-341376-1,138277-501,783-2,328
Income taxes payable128-277-34-1,421-21-266124-3,291827-2,359560-5403802141,023
Noncurrent liabilities-98-7-1,747-132190-277-809-123-266-237-453484-545456-49
Other1602621,203-563985-2371,091674322,4261,7581,4732,3141,416
Net Cash Provided by Operating Activities10,82212,38310,02211,6547,86012,42110,3766,44710,92213,44010,253---21,468
Capital expenditures-------------3,8633,372
Purchases of securities and other investments-------------955519
Proceeds from sale of Seagen Inc. common stock-------------1,145-
Proceeds from Sale and Maturity of Other Investments-------------1,658377
Acquisition of Eyebiotech Limited, net of cash acquired-------------1,3271,344
Acquisition of Elanco Animal Health Incorporated aqua business--------------1,303
Acquisition of Harpoon Therapeutics, Inc., net of cash acquired256373-2461811467803964312941,365179121-746
Acquisition of MK-1045 from Curon Pharmaceutical--------------700
Acquisition of Prometheus Biosciences, Inc., net of cash acquired---------1,0402,6961,554---
Acquisition of Imago BioSciences Inc., net of cash acquired----3,7007,598---3,6202,54511,174---
Other-150116-1735780-82-453-38-102-378-13091-3236127
Net Cash Used in Investing Activities-3,497-2,890-6,805-3,148-374-4,758-3,2102,6794,314-2,629-9,443----7,734
Payments on debt1,3411,547221,7756,6172,9062,3861,1034,287-1,9572,3192,2511,7551,290
Proceeds from issuance of debt--------------3,599
Purchases of treasury stock1,5931,9212,5916,5167,7034,1863,4344,0149,0914,7801,281840-1,3461,306
Dividends paid to stockholders4,7344,6915,1165,1575,1705,1175,1245,1675,1725,6956,2156,6107,0127,4457,840
Proceeds from Stock Options Exercised3633211,3101,2101,56048593949959136189202384125177
Other-106-22866020856-118-195-3255-436-286-240-328-372
Net Cash Used in Financing Activities-5,441-6,904-3,267-5,990-15,113-5,270-9,044-10,006-13,160-8,861-2,832----7,032
Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash---------20517253-133-41023-293
Net Increase (Decrease) in Cash, Cash Equivalents and Restricted Cash--------1,8711,967-1,769144,606-5,8646,409